Skip to content
Medical Health Aged Care

Canberra lightens the overload of Australia’s most common genetic disorder

Haemochromatosis Australia 2 mins read

MEDIA RELEASE 

The National Carillon and Old Canberra House are among 100 well-known buildings and landmarks across Australia will turn red from tonight until 7 June, shining a light on an extremely common genetic condition that most people have never heard of.

It is part of a worldwide initiative to raise awareness of haemochromatosis – also known as iron overload – and to prompt people to get tested. Most people know that having too little iron in your body can cause anaemia, which is characterised by tiredness and lethargy, but few people know that the same symptoms can also be caused by having too much iron.

The hereditary condition, which is passed on from both biological parents, is simple to detect and treat but if undiagnosed or ignored can lead to serious and life-threatening illness, including liver disease and diabetes. One in seven Australians carry one copy of the defective gene, while and one in 200 Australians have two copies, which puts them at high risk of developing the condition.

Dr Dan Johnstone, an iron researcher who also has the condition, says early detection is key to minimising or preventing permanent damage. “Awareness of haemochromatosis is more important now than ever as early diagnosis will help save lives, cut health costs and reduce unnecessary suffering for so many individuals and families. Everybody is different; some people will have early symptoms of fatigue or joint aches while others won’t know they have the condition until the damage is already done. Anyone who suspects they may have this condition should ask their GP for a blood test. Haemochromatosis is not a burden in your life if you get on to it early. Early diagnosis is key to managing and reducing complications. It is usually managed by a regime of therapeutic blood donations, at an Australian Red Cross Lifeblood donor centre. This is a classic win-win situation, benefiting both the individual and the community,” said Dr Johnstone.

Haemochromatosis Australia spokesperson, Tony Moorhead, said, “Despite being the most common genetic disorder in Australia, haemochromatosis is often underdiagnosed because people don’t know about it and symptoms are non-specific. Unfortunately, most of those affected aren’t diagnosed until aged in their mid-forties and already suffering ill health. “There are people with the condition who should have been diagnosed decades earlier. This would have reduced the suffering, medical cost and even loss of life that results from iron overload. If haemochromatosis is detected early enough it is completely preventable – those affected need never get sick, they simply need to donate blood to maintain normal iron levels and their health.” Mr Moorhead says. “Hereditary haemochromatosis is estimated to cost Australia’s health system about $280 million annually and to add further cost burdens by compounding other chronic conditions.” Haemochromatosis is easy to test, simple to treat but tragic to ignore. -

 

ENDS Landmarks lighting up can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/


Key Facts:

* Australia's most common genetic disorder, that most have never heard of

* World Haemochromatosis Awareness Week June 1 - 7 

*Interviews available

* Landmarks lighting up red can be found here: www.ha.org.au/whats-on/world-haemochromatosis-week/lighten-the-overload/ 

* Interviews available


About us:

To find out more visit www.ha.org.au/haemochromatosis


Contact details:

Kellie Curtain M: 0412339690 [email protected]

Media

More from this category

  • Medical Health Aged Care
  • 18/03/2026
  • 18:41
Samsung Bioepis Co., Ltd.

Samsung Bioepis Enters into Partnership Agreement with Sandoz for Up to Five Next-Generation Biosimilar Candidates

The agreement covers up to five assets, including SB36, a biosimilar candidate referencing Entyvio (vedolizumab), for collaboration of development and commercialization in global markets excluding China, Hong Kong, Taiwan, Macau, and Republic of KoreaSamsung Bioepis continues to pave the way for access to life-changing medicines by advancing a biosimilar pipeline across immunology and oncology   INCHEON, Korea--BUSINESS WIRE-- Samsung Bioepis Co., Ltd. announced today that the company has entered into a global license, development and commercialization agreement (DCA) with Sandoz for up to five biosimilar candidates under development by Samsung Bioepis, including SB36, a biosimilar candidate referencing Entyvio1 (vedolizumab). The…

  • Contains:
  • Medical Health Aged Care
  • 18/03/2026
  • 16:49
Palliative Care Australia

Better end-of-life care for older Australians must be the next step in aged care reform

Palliative Care Australia this week brought leaders from aged care, palliative care, health, advocacy, research and policy together in Melbourne for its inauguralPalliative Care…

  • Contains:
  • Indigenous, Medical Health Aged Care
  • 18/03/2026
  • 07:21
Australian and New Zealand Journal of Public Health / Public Health Association of Australia

Emerging Aboriginal leaders call for greater Indigenous control over native foods

As Australia’s native food industry booms, experts say Indigenous people must have a seat at the table Aboriginal leaders and advocates have joined together today to call out commercial companies exploiting native food knowledge without adequate community engagement. They are urging government action to ensure Indigenous people can better lead and control the access and benefits that arise from their traditional foods and knowledge. The new evidence-based commentary, published in the Australian and New Zealand Journal of Public Health, represents the collective view of six leading Aboriginal academics and one non-Indigenous researcher with expertise across bush food, traditional Indigenous medicines,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.